Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

  • LAST PRICE
    22.8600
  • TODAY'S CHANGE (%)
    -0.1500 (-0.6519%)
  • Bid / Lots
    20.0100/ 1
  • Ask / Lots
    28.2500/ 1
  • Open / Previous Close
    23.0100 / 23.0100
  • Day Range
    22.6200
    23.3700
  • 52 Week Range
    14.1200
    28.1500
  • Volume
    353,800

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
KNSA
Kiniksa Pharmaceuticals Ltd
1.7B
-144.3x
---
DVAX
Dynavax Technologies Corp
1.7B
128.7x
---
BCRX
BioCryst Pharmaceuticals Inc
1.6B
-12.8x
---
CDNA
CareDx Inc
1.3B
-8.8x
---
MRVI
Maravai LifeSciences Holdings Inc
1.3B
-5.1x
---
XNCR
Xencor Inc
1.7B
-7.4x
---
As of 2024-11-10

Company Information

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).

Contact Information

Headquarters
Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
Phone
---
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Sanjiv Patel
Chief Financial Officer, Senior Vice President
Mark Ragosa
Chief Operating Officer, Senior Vice President
Eben Tessari
Senior Vice President, Chief Commercial Officer
Ross Moat
Senior Vice President, Chief Medical Officer
John Paolini

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.7B
Revenue (TTM)
$384.1M
Shares Outstanding
72.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.28
EPS
$-0.16
Book Value
$6.23
P/E Ratio
-144.3x
Price/Sales (TTM)
4.3
Price/Cash Flow (TTM)
---
Operating Margin
-6.83%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.